TY - JOUR
T1 - Pathways towards human immunodeficiency virus elimination
AU - Dash, Prasanta K.
AU - Kevadiya, Bhavesh D.
AU - Su, Hang
AU - Banoub, Mary G.
AU - Gendelman, Howard E.
N1 - Funding Information:
This work is supported by the University of Nebraska Foundation, which includes donations from the Carol Swarts, M.D., Emerging Neuroscience Research Laboratory , the Margaret R. Larson Professorship, and the Frances and Louie Blumkin, and Harriet Singer Endowments; the University of Nebraska Medical Center's Vice Chancellor for Research Core Facilities , and the National Institutes of Health grants 1R01AI145542-01A1 , P01 DA028555 , R01 NS36126 , P01 NS31492 , 2R01 NS034239 , P01 MH64570 , P01 NS43985 , P30 MH062261 , R01 AG043540 , and 1 R56 AI138613-01A1 .
PY - 2020/3
Y1 - 2020/3
N2 - Antiretroviral therapy (ART) suppresses human immunodeficiency virus (HIV) infection. Research seeking to transform viral suppression into elimination has generated novel immune, chemical and molecular antiviral agents. However, none, to date, have excised latent integrated proviral DNA or removed infected cells from infected persons. These efforts included, but are not limited to, broadly neutralizing antibodies, “shock” and “kill” latency-reversing agents, innate immune regulators, and sequential long-acting antiretroviral nanoformulated prodrugs and CRISPR-Cas9 gene editing. While, the latter, enabled the complete excision of latent HIV-1 from the host genome success was so far limited. We contend that improvements in antiretroviral delivery, potency, agent specificity, or combinatorial therapies can provide a pathway towards complete HIV elimination.
AB - Antiretroviral therapy (ART) suppresses human immunodeficiency virus (HIV) infection. Research seeking to transform viral suppression into elimination has generated novel immune, chemical and molecular antiviral agents. However, none, to date, have excised latent integrated proviral DNA or removed infected cells from infected persons. These efforts included, but are not limited to, broadly neutralizing antibodies, “shock” and “kill” latency-reversing agents, innate immune regulators, and sequential long-acting antiretroviral nanoformulated prodrugs and CRISPR-Cas9 gene editing. While, the latter, enabled the complete excision of latent HIV-1 from the host genome success was so far limited. We contend that improvements in antiretroviral delivery, potency, agent specificity, or combinatorial therapies can provide a pathway towards complete HIV elimination.
KW - Antiretroviral therapy
KW - Broadly neutralizing antibodies
KW - CRISPR-Cas9 gene editing
KW - HIV-1 tissue reservoirs
KW - Latency reversing agents
KW - Long-acting slow-effective release antiretroviral therapy
UR - http://www.scopus.com/inward/record.url?scp=85079843684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079843684&partnerID=8YFLogxK
U2 - 10.1016/j.ebiom.2020.102667
DO - 10.1016/j.ebiom.2020.102667
M3 - Review article
C2 - 32114397
AN - SCOPUS:85079843684
VL - 53
JO - EBioMedicine
JF - EBioMedicine
SN - 2352-3964
M1 - 102667
ER -